Peter Wood

1.7k total citations · 1 hit paper
36 papers, 1.1k citations indexed

About

Peter Wood is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Peter Wood has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 10 papers in Genetics and 8 papers in Oncology. Recurrent topics in Peter Wood's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Peter Wood is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Peter Wood collaborates with scholars based in Australia, New Zealand and United States. Peter Wood's co-authors include Samar Issa, David Simpson, David MacDonald, Kathryn S. Kolibaba, Ian W. Flinn, John M. Burke, Tim E. Hawkins, Brad S. Kahl, Doreen M. Hallman and Richard van der Jagt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Circulation Research.

In The Last Decade

Peter Wood

36 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

2014 419 citations Ian W. Flinn, Richard van der Jagt et al. Blood profile →

Peers

Countries citing papers authored by Peter Wood

Since Specialization

Citations

This map shows the geographic impact of Peter Wood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Wood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Wood more than expected).

Fields of papers citing papers by Peter Wood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Wood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Wood. The network helps show where Peter Wood may publish in the future.

Co-authorship network of co-authors of Peter Wood

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Wood. A scholar is included among the top collaborators of Peter Wood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Wood. Peter Wood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial 2017 ·Blood ·Brad S. Kahl, John M. Burke, Richard van der Jagt, Julie Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, Ling Chen, Ian W. Flinn	10
2	FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY 2017 ·Hematological Oncology ·Ian W. Flinn, Richard van der Jagt, Julie Chang, Peter Wood, (unknown), David MacDonald, Judith Trotman, David Simpson, Kathryn S. Kolibaba, Samar Issa, Doreen M. Hallman, (unknown), John M. Burke	9
3	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma 2016 ·Clinical Cancer Research ·Colm Keane, Clare Gould, Kimberley Jones, David Hamm, Dipti Talaulikar, Jonathan Ellis, Frank Vari, Simone Birch, Erica Han, Peter Wood, Kim‐Anh Lê Cao, Michael R. Green, Pauline Crooks, Sanjiv Jain, Joshua W.D. Tobin, Raymond J. Steptoe, Maher K. Gandhi	63
4	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study 2016 ·Blood ·Constantine S. Tam, Judith Trotman, Stephen Opat, Paula Marlton, Gavin Cull, David Simpson, Matthew Ku, David Ritchie, Emma Verner, (unknown), Mary Ann Anderson, Peter Wood, Mark Kirschbaum, Lai Wang, Ling Xue, (unknown), Eric Hedrick, John F. Seymour, Andrew W. Roberts	11
5	Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma 2016 ·Clinical Lymphoma Myeloma & Leukemia ·John M. Burke, (unknown), Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Mihaela Munteanu, Timothy W. Victor, Ian W. Flinn	14
6	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study breakdown → 2014 ·Blood ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke	419
7	Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL). 2013 ·Journal of Clinical Oncology ·Ian W. Flinn, (unknown), Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke	3
8	Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma 2012 ·Blood ·John M. Burke, Richard H. van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Richard E. White, Mihaela Munteanu, Regina Clementi, Ling Chen, Ian W. Flinn	5
9	Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non‐Hodgkin's lymphoma 2011 ·Genes Chromosomes and Cancer ·Michael R. Green, (unknown), Maher K. Gandhi, Rod A. Lea, (unknown), Peter Wood, Paula Marlton, Lyn R. Griffiths	41
10	A new method to detect loss of heterozygosity using cohort heterozygosity comparisons 2010 ·BMC Cancer ·Michael R. Green, (unknown), Peter Wood, (unknown), Rod A. Lea, Paula Marlton, Lyn R. Griffiths	7
11	Acute response of blood glucose to short-term exercise training in patients with type 2 diabetes 2010 ·Journal of science and medicine in sport ·M. Hordern, Thomas H. Marwick, Peter Wood, (unknown), Johannes B. Prins, Jeff S. Coombes	19
12	A novel in vivo ovine model of transfusion‐related acute lung injury (TRALI) 2010 ·Vox Sanguinis ·John‐Paul Tung, Yoke Lin Fung, Maria Nataatmadja, (unknown), (unknown), Kristin Wilson, Adrian Barnett, Peter Wood, Christopher C. Silliman, John F. Fraser	48
13	Respiratory burst function of ovine neutrophils 2009 ·BMC Immunology ·John‐Paul Tung, John F. Fraser, Peter Wood, Yoke Lin Fung	21
14	High‐dose tirofiban with enoxaparin and inflammatory markers in high‐risk percutaneous intervention 2009 ·European Journal of Clinical Investigation ·D. Walters, Michael Ray, Peter Wood, (unknown), J. H. N. Bett, Con Aroney	5
15	CARDIOPULMONARY BYPASS INDUCES ENDURING ALTERATIONS TO HOST NEUTROPHIL PHYSIOLOGY 2008 ·Shock ·Yoke Lin Fung, Christopher C. Silliman, R. M. Minchinton, Peter Wood, John F. Fraser	13
16	The systemic inflammatory response syndrome induces functional changes and relative hyporesponsiveness in neutrophils 2008 ·Journal of Critical Care ·Yoke Lin Fung, John F. Fraser, Peter Wood, R. M. Minchinton, Christopher C. Silliman	18
17	Neutrophil priming and activation in critically ill patients 2005 ·Queensland's institutional digital repository (The University of Queensland) ·Yoke Lin Fung, R. M. Minchinton, (unknown), John F. Fraser, Peter Wood	1
18	Point‐of‐care testing shows clinically relevant variation in the degree of inhibition of platelets by standard‐dose abciximab therapy during percutaneous coronary intervention 2004 ·Catheterization and Cardiovascular Interventions ·Michael Ray, D. Walters, Nicholas Bett, James D. Cameron, Peter Wood, Con Aroney	6
19	Platelet–monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab 2004 ·International Journal of Cardiology ·Michael Ray, D. Walters, (unknown), James D. Cameron, Peter Wood, Nicholas Aroney	28
20	Histoplasma capsulatum in peripheral blood smears 2002 ·British Journal of Haematology ·Glen Kennedy, Jennifer Curnow, (unknown), Bronwyn Williams, Peter Wood, (unknown), Emma S. McBryde, Marion L. Woods	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact